Changes in the type and amount of spending disclosed by Australian pharmaceutical companies: An observational study

Abstract

Objectives To describe and quantify disclosed payments from the pharmaceutical industry to the healthcare sector, and to examine the impact of the 2015 changes to Australia's self-regulated system of transparency. Design Observational database study. Setting Australia. Participants Publicly available reports submitted by members of Australian pharmaceutical industry trade organisations, Medicines Australia and the Generic and Biosimilar Medicines Association (GBMA) (October 2011-December 2017). Exposure Changes to transparency reporting requirements with the updates of pharmaceutical industry Codes of Conduct in 2015. Main outcome measures Elements of healthcare sector spending that members ..